199 related articles for article (PubMed ID: 31669219)
21. Synthesis, Structural Characterization and Docking Studies of Sulfamoyl- Phenyl Acid Esters as Dipeptidyl Peptidase-IV Inhibitors.
Khalaf RA; Sabbah D; Al-Shalabi E; Al-Sheikh I; Albadawi G; Abu Sheikha G
Curr Comput Aided Drug Des; 2018; 14(2):142-151. PubMed ID: 29521244
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
[TBL] [Abstract][Full Text] [Related]
24. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
25. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Deng X; Han L; Zhou J; Zhang H; Li Q
Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
[TBL] [Abstract][Full Text] [Related]
26. Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents.
Savateev K; Fedotov V; Butorin I; Eltsov O; Slepukhin P; Ulomsky E; Rusinov V; Litvinov R; Babkov D; Khokhlacheva E; Radaev P; Vassiliev P; Spasov A
Eur J Med Chem; 2020 Jan; 185():111808. PubMed ID: 31683103
[TBL] [Abstract][Full Text] [Related]
27. Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV.
Huang PK; Lin SR; Chang CH; Tsai MJ; Lee DN; Weng CF
Sci Rep; 2019 Oct; 9(1):15585. PubMed ID: 31666589
[TBL] [Abstract][Full Text] [Related]
28. DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis.
Khalaf RA; Masalha D; Sabbah D
Curr Comput Aided Drug Des; 2020; 16(3):295-307. PubMed ID: 30526469
[TBL] [Abstract][Full Text] [Related]
29. Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li Q; Deng X; Jiang N; Meng L; Xing J; Jiang W; Xu Y
Eur J Med Chem; 2021 Dec; 225():113765. PubMed ID: 34399391
[TBL] [Abstract][Full Text] [Related]
30. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
Hussain H; Abbas G; Green IR; Ali I
Expert Opin Ther Pat; 2019 Jul; 29(7):535-553. PubMed ID: 31203700
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors.
Jiang T; Zhou Y; Zhu J; Chen Z; Sun P; Zhang Q; Wang Z; Shao Q; Jiang X; Li B; Wang H; Zhu W; Shen J
Arch Pharm (Weinheim); 2015 Jun; 348(6):399-407. PubMed ID: 25871012
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
Li Q; Han L; Zhang B; Zhou J; Zhang H
Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
[TBL] [Abstract][Full Text] [Related]
34. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.
Xing J; Li Q; Zhang S; Liu H; Zhao L; Cheng H; Zhang Y; Zhou J; Zhang H
Chem Biol Drug Des; 2014 Sep; 84(3):364-77. PubMed ID: 24674599
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.
Cho TP; Long YF; Gang LZ; Yang W; Jun LH; Yuan SG; Hong FJ; Lin W; Liang GD; Lei Z; Jing LJ; Shen GA; Hong SG; Dan W; Ying F; Ke YP; Ying L; Jun F; Tai MX
Bioorg Med Chem Lett; 2010 Jun; 20(12):3565-8. PubMed ID: 20488702
[TBL] [Abstract][Full Text] [Related]
36. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, biological evaluation of 3,5-diaryl-4,5-dihydro-1H-pyrazole carbaldehydes as non-purine xanthine oxidase inhibitors: Tracing the anticancer mechanism via xanthine oxidase inhibition.
Joshi G; Sharma M; Kalra S; Gavande NS; Singh S; Kumar R
Bioorg Chem; 2021 Feb; 107():104620. PubMed ID: 33454509
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus.
Kuranov SO; Tsypysheva IP; Khvostov MV; Zainullina LF; Borisevich SS; Vakhitova YV; Luzina OA; Salakhutdinov NF
Bioorg Med Chem; 2018 Aug; 26(15):4402-4409. PubMed ID: 30056037
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors.
Mo DW; Dong S; Sun H; Chen JS; Pang JX; Xi BM; Chen WH
Bioorg Med Chem Lett; 2015 May; 25(9):1872-5. PubMed ID: 25838146
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of dipeptidyl peptidase-4 averts free fatty acids deposition in the hearts of oral estrogen-progestin contraceptive-induced hyperinsulinemic female rats.
Adegoke TE; Sabinari IW; Areola ED; Ajao F; Asafa OO; Soluoku TK; Bello A; Adesanmi AM; Yusuf SO; Omoleye A; Ayinla MT; Olatunji LA
Can J Physiol Pharmacol; 2021 Dec; 99(12):1316-1323. PubMed ID: 34310895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
